ES2527437T3 - Procedimiento para la producción de 2-[4-(3- y 2-fluorobenciloxi)bencilamino]propanamidas - Google Patents

Procedimiento para la producción de 2-[4-(3- y 2-fluorobenciloxi)bencilamino]propanamidas Download PDF

Info

Publication number
ES2527437T3
ES2527437T3 ES07764601.6T ES07764601T ES2527437T3 ES 2527437 T3 ES2527437 T3 ES 2527437T3 ES 07764601 T ES07764601 T ES 07764601T ES 2527437 T3 ES2527437 T3 ES 2527437T3
Authority
ES
Spain
Prior art keywords
fluorobenzyloxy
benzylamino
salts
formula
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07764601.6T
Other languages
English (en)
Inventor
Elena Barbanti
Carla Caccia
Patricia Salvati
Francesco Velardi
Tiziano Ruffilli
Luigi Bogogna
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Newron Pharmaceuticals SpA
Original Assignee
Newron Pharmaceuticals SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101658&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2527437(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Newron Pharmaceuticals SpA filed Critical Newron Pharmaceuticals SpA
Application granted granted Critical
Publication of ES2527437T3 publication Critical patent/ES2527437T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/08—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/12—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups
    • C07C233/13—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by halogen atoms or by nitro or nitroso groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/10—Preparation of carboxylic acid amides from compounds not provided for in groups C07C231/02 - C07C231/08
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/16—Preparation of optical isomers
    • C07C231/18—Preparation of optical isomers by stereospecific synthesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un procedimiento para producir (S)-2-[4-(3-fluorobenciloxi)bencilamino]propanamida (safinamida) o (S)-2-[4- (2-fluorobenciloxi)bencilamino]propanamida (ralfinamida) de alto grado de pureza de fórmulas (Ia) y (Ib)**Fórmula** y sus sales con un ácido farmacéuticamente aceptable, caracterizado porque una base de Schiff intermedia respectivamente de fórmula (VIa) o (VIb)**Fórmula** se envía a una hidrogenación catalítica con hidrógeno gas en presencia de un catalizador heterogéneo en un disolvente orgánico prótico y, cuando la safinamida o la ralfinamida se obtienen en forma de la base libre, y, cuando se desea una de sus sales con un ácido farmacéuticamente aceptable, se convierte dicha forma de base libre en una de sus sales con un ácido farmacéuticamente aceptable.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23
imagen24
imagen25
imagen26
imagen27
imagen28
imagen29
imagen30
imagen31

Claims (1)

  1. imagen1
    imagen2
    imagen3
    imagen4
ES07764601.6T 2006-06-19 2007-06-08 Procedimiento para la producción de 2-[4-(3- y 2-fluorobenciloxi)bencilamino]propanamidas Active ES2527437T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06012565 2006-06-19
EP06012565 2006-06-19
PCT/EP2007/005105 WO2007147491A1 (en) 2006-06-19 2007-06-08 Process for the production of 2- [4 - ( 3- and 2-flu0r0benzyl0xy) benzylamin0] propan amides

Publications (1)

Publication Number Publication Date
ES2527437T3 true ES2527437T3 (es) 2015-01-26

Family

ID=37101658

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12163085.9T Active ES2602069T3 (es) 2006-06-19 2007-06-08 2-[4-(3- y 2-fluorobenciloxi)bencilamino]propanamidas de grado de pureza elevado para la utilización como medicamentos y formulaciones farmacéuticas que las contienen
ES07764601.6T Active ES2527437T3 (es) 2006-06-19 2007-06-08 Procedimiento para la producción de 2-[4-(3- y 2-fluorobenciloxi)bencilamino]propanamidas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES12163085.9T Active ES2602069T3 (es) 2006-06-19 2007-06-08 2-[4-(3- y 2-fluorobenciloxi)bencilamino]propanamidas de grado de pureza elevado para la utilización como medicamentos y formulaciones farmacéuticas que las contienen

Country Status (27)

Country Link
US (2) US8076515B2 (es)
EP (2) EP2029524B1 (es)
JP (2) JP5240476B2 (es)
KR (2) KR101491541B1 (es)
CN (2) CN103284984B (es)
AR (1) AR061510A1 (es)
AU (1) AU2007263328C1 (es)
BR (1) BRPI0712936B8 (es)
CA (1) CA2653012C (es)
CY (2) CY1115951T1 (es)
DK (2) DK2029524T3 (es)
EA (2) EA017123B1 (es)
ES (2) ES2602069T3 (es)
HK (1) HK1130245A1 (es)
HR (2) HRP20150136T1 (es)
HU (1) HUE030233T2 (es)
IL (1) IL195294A (es)
LT (1) LT2474521T (es)
MX (2) MX342698B (es)
NO (2) NO342018B1 (es)
NZ (2) NZ595737A (es)
PL (2) PL2474521T3 (es)
PT (2) PT2029524E (es)
RS (2) RS53824B1 (es)
SI (2) SI2029524T1 (es)
TW (2) TWI412512B (es)
WO (1) WO2007147491A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1658062E (pt) * 2003-08-25 2010-03-31 Newron Pharm Spa Derivados de alfa-amino amida úteis como agentes antiinflamatórios
BRPI0712936B8 (pt) * 2006-06-19 2021-05-25 Newron Pharm Spa processo para a produção de 2-[4-(3- e 2-fluorbenziloxi)benzila-mino]propanamidas
CN101896456B (zh) * 2007-12-11 2014-10-22 纽朗制药有限公司 具有高纯度的2-[4-(3-或2-氟苄氧基)苄氨基]丙酰胺类的生产方法
EP2314569A1 (en) * 2009-10-22 2011-04-27 Merck Patent GmbH Novel polymorphic forms of (S)-2-[4-(3-Fluoro-benzyloxy)-benzylamino]-propionamide mesylate salt and processes of manufacturing thereof
DK2563355T3 (en) 2010-04-27 2016-09-12 Newron Pharm Spa A process for the preparation of ralfinamide-methanesulphonate or R-enantiomers thereof.
EP2925751A1 (en) 2012-12-03 2015-10-07 F. Hoffmann-La Roche AG Substituted isoxazole amide compounds as inhibitors of stearoyl-coa desaturase 1 (scd1)
WO2014178083A1 (en) 2013-05-03 2014-11-06 Council Of Scientific & Industrial Research An improved synthesis of anti-parkinson agent
CN104292128A (zh) * 2014-07-01 2015-01-21 南京正科制药有限公司 一种沙芬酰胺晶型a
JP6466109B2 (ja) * 2014-09-09 2019-02-06 東ソー・ファインケム株式会社 ２−ベンジルオキシ−５−（トリフルオロメチル）ピリミジン誘導体及びその製造方法
CN105017060B (zh) * 2015-07-03 2017-06-16 南京正大天晴制药有限公司 一种沙芬酰胺新晶型及其制备方法
CN113072436A (zh) * 2015-07-24 2021-07-06 上海医药集团股份有限公司 一种苄基芳基醚的制备方法
CN105061245A (zh) * 2015-08-25 2015-11-18 成都维恒医药科技有限公司 一种高纯度沙芬酰胺的制备方法
CN106220525A (zh) * 2016-07-31 2016-12-14 合肥远志医药科技开发有限公司 一种工业化沙芬酰胺甲磺酸盐的制备方法
CN106336363B (zh) * 2016-08-22 2018-10-30 上海医药集团股份有限公司 一种沙芬酰胺甲磺酸盐晶型c及其制备方法
CN106565521B (zh) * 2016-08-24 2019-03-08 浙江美诺华药物化学有限公司 (s)-2-[3-(3-氟苄基)-4-(3-氟苄氧基)苄氨基]丙酰胺及其盐的制备方法
CN106596828B (zh) * 2016-12-15 2018-09-25 扬子江药业集团有限公司 一种甲磺酸沙芬酰胺有关物质的检测方法
CN107271600B (zh) * 2017-07-28 2019-01-25 成都百裕制药股份有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体杂质含量的检测方法
CN107857713A (zh) * 2017-11-23 2018-03-30 江苏恒盛药业有限公司 一种沙芬酰胺氢溴酸盐及其一种晶型
CN107759487A (zh) * 2017-11-23 2018-03-06 江苏恒盛药业有限公司 一种沙芬酰胺盐酸盐及其一种晶型以及制备方法
WO2019167085A1 (en) * 2018-03-01 2019-09-06 Msn Laboratories Private Limited, R&D Center Process for the preparation of (s)-2-[[4-[(3-fluorophenyl)methoxy]phenyl]methyl]amino propanamide methanesulfonate
US11111208B2 (en) 2019-06-17 2021-09-07 RK Pharma Solutions LLC Process for the preparation of safinamide mesylate intermediate
US11225457B2 (en) 2019-08-06 2022-01-18 Medichem, S.A. Process for preparing safinamide
CN111122736B (zh) * 2019-12-30 2021-03-12 北京鑫开元医药科技有限公司海南分公司 一种用于检测布瓦西坦中间体中对映异构体的方法
CN113214097B (zh) * 2020-01-21 2022-08-30 厦门大学 治疗阿尔茨海默病的化合物
CN112028754A (zh) * 2020-06-17 2020-12-04 浙江美诺华药物化学有限公司 一种甲磺酸沙芬酰胺中间体的制备方法
CN114088830B (zh) * 2021-11-10 2022-09-23 石家庄四药有限公司 一种4-(3-氟苄氧基)苯甲醛中异构体的检测方法
CN116008439B (zh) * 2023-02-20 2023-10-27 山东绿叶制药有限公司 一种检测2,6-二氧杂螺[4,5]癸烷类化合物或其盐中杂质的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94466A (en) 1989-05-25 1995-01-24 Erba Carlo Spa Pharmaceutical preparations containing the history of A-amino carboxamide N-phenylalkyl are converted into such new compounds and their preparation
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
EP0974351A3 (en) * 1998-04-24 2000-12-13 Jouveinal Medicament for preventing and treating gastrointestinal damage
IL151952A0 (en) 2000-03-31 2003-04-10 Euro Celtique Sa Aminopyridine derivatives and pharmaceutical compositions containing the same
ES2253579T3 (es) * 2001-09-03 2006-06-01 Newron Pharmaceuticals S.P.A. Composicion farmaceutica que comprende gabapentina o un analogo suyo y una alfa-aminoamida y su uso analgesico.
EP1438956A1 (en) 2003-01-16 2004-07-21 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful as antimigraine agents
AU2004207009A1 (en) * 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
US20040209960A1 (en) * 2003-01-30 2004-10-21 Dynogen Pharmaceuticals, Inc. Methods of treating lower urinary tract disorders using sodium channell modulators
AR044007A1 (es) * 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
TW200507850A (en) * 2003-07-25 2005-03-01 Kyowa Hakko Kogyo Kk Pharmaceutical composition
PT1658062E (pt) * 2003-08-25 2010-03-31 Newron Pharm Spa Derivados de alfa-amino amida úteis como agentes antiinflamatórios
EP1524267A1 (en) 2003-10-15 2005-04-20 Newron Pharmaceuticals S.p.A. Substituted benzylaminoalkylene heterocycles
EP1557166A1 (en) 2004-01-21 2005-07-27 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders
EP1588704A1 (en) * 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of restless legs syndrome and addictive disorders
US20080096965A1 (en) 2004-09-10 2008-04-24 Newron Pharmaceuticals S.P.A. (Halobenzyloxy) Benzylamino-Propanamides as Sodium and/or Calcium Channel Selective Modulators
EP1870097A1 (en) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Alpha-aminoamide derivatives useful in the treatment of cognitive disorders
BRPI0712936B8 (pt) * 2006-06-19 2021-05-25 Newron Pharm Spa processo para a produção de 2-[4-(3- e 2-fluorbenziloxi)benzila-mino]propanamidas
CN101896456B (zh) * 2007-12-11 2014-10-22 纽朗制药有限公司 具有高纯度的2-[4-(3-或2-氟苄氧基)苄氨基]丙酰胺类的生产方法
NZ586182A (en) * 2007-12-19 2012-02-24 Newron Pharm Spa Alpha-aminoamide derivatives useful in the treatment of psychiatric disorders

Also Published As

Publication number Publication date
JP5240476B2 (ja) 2013-07-17
PL2029524T3 (pl) 2015-04-30
CN101472880A (zh) 2009-07-01
HK1130245A1 (en) 2009-12-24
NO20090231L (no) 2009-01-16
JP2013139446A (ja) 2013-07-18
PT2474521T (pt) 2016-11-10
KR101410291B1 (ko) 2014-06-20
AU2007263328A2 (en) 2009-02-19
DK2474521T3 (en) 2016-10-31
PL2474521T3 (pl) 2017-01-31
EA200970028A1 (ru) 2009-06-30
LT2474521T (lt) 2016-11-25
KR101491541B1 (ko) 2015-02-09
KR20090021392A (ko) 2009-03-03
CA2653012C (en) 2014-08-05
PT2029524E (pt) 2015-03-09
KR20140027563A (ko) 2014-03-06
BRPI0712936A2 (pt) 2012-12-18
AU2007263328A1 (en) 2007-12-27
EP2474521B1 (en) 2016-08-10
SI2474521T1 (sl) 2016-12-30
EA201101308A1 (ru) 2012-02-28
TW201313662A (zh) 2013-04-01
TW200815322A (en) 2008-04-01
HRP20161456T1 (hr) 2016-12-16
RS53824B1 (en) 2015-06-30
IL195294A0 (en) 2009-08-03
NZ572798A (en) 2011-11-25
US20120157712A1 (en) 2012-06-21
TWI393700B (zh) 2013-04-21
CN103284984B (zh) 2016-08-03
JP2009541232A (ja) 2009-11-26
NO342644B1 (no) 2018-06-25
RS55464B1 (sr) 2017-04-28
US8278485B2 (en) 2012-10-02
WO2007147491A1 (en) 2007-12-27
TWI412512B (zh) 2013-10-21
SI2029524T1 (sl) 2015-03-31
NO342018B1 (no) 2018-03-12
MX342698B (es) 2016-10-10
US20090156678A1 (en) 2009-06-18
CA2653012A1 (en) 2007-12-27
NO20171916A1 (no) 2009-01-16
BRPI0712936B1 (pt) 2021-02-23
EP2029524B1 (en) 2014-11-26
EP2029524A1 (en) 2009-03-04
JP5795342B2 (ja) 2015-10-14
BRPI0712936B8 (pt) 2021-05-25
AU2007263328C1 (en) 2012-09-06
EA025326B1 (ru) 2016-12-30
NZ595737A (en) 2013-04-26
HUE030233T2 (en) 2017-04-28
ES2602069T3 (es) 2017-02-17
MX2008015704A (es) 2009-01-09
CY1118113T1 (el) 2017-06-28
EP2474521A1 (en) 2012-07-11
US8076515B2 (en) 2011-12-13
AR061510A1 (es) 2008-09-03
EA017123B1 (ru) 2012-10-30
HRP20150136T1 (en) 2015-03-13
CN103284984A (zh) 2013-09-11
CN101472880B (zh) 2013-04-24
AU2007263328B2 (en) 2012-03-22
IL195294A (en) 2015-03-31
DK2029524T3 (da) 2015-02-23
CY1115951T1 (el) 2017-01-25

Similar Documents

Publication Publication Date Title
ES2527437T3 (es) Procedimiento para la producción de 2-[4-(3- y 2-fluorobenciloxi)bencilamino]propanamidas
ES2485890T3 (es) Proceso para la producción de derivados de amina ópticamente activos
ES2519446T3 (es) Proceso para la preparación de ácido 4-amino-butírico sustituido con biarilo o derivados del mismo y su uso en la producción de inhibidores de NEP
CU23465B7 (es) Nuevo proceso para la síntesis de ivabradine y sales de adición de la misma con un ácido farmacéuticamente aceptable
BRPI0820657A2 (pt) Processo para a produção de 2-[4-(3- ou 2-fluorobenzilóxi)benzilamino]pro-panamidas com alto grau de pureza
BRPI0815534A2 (pt) "método para produzir pelo menos um alcool c2-c4 a partir de gás de síntese, método para produzir etanol a partir de gás de sintese e aparelho capaz de reproduzir pelo menos um alcóol c2-c4 a partir de gás de síntese"
MX2009013480A (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable.
CY1105826T1 (el) Μεθοδος συνθεσης του (1s)-4,5-διμεθοξυ-1-(μεθυλαμινομεθυλ)βενζοκυκλοβουτανιου και των αλατων προσθηκης αυτου και εφαρμογη στη συνθεση της ιβαβραδινης και των αλατων προσθηκης αυτης με φαρμακευτικως αποδεκτο οξυ
ATE402173T1 (de) Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
AR048235A1 (es) Un procedimiento para la sintesis de (7-metoxi-3,4-dihidro-1-naftalenil)acetonitrilo y su aplicacion en la sintesis de agomelatina
ES2575666T3 (es) Proceso de fabricación de un agente farmacéuticamente activo
EA200500201A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
ATE449098T1 (de) Stereoselektive synthese bestimmter trifluormethylsubstituierter alkohole
CA2818957A1 (fr) Procede d'elimination de derives a base de siloxane d'une phase organique liquide
DK1720823T3 (da) Ny fremgangsmåde til syntese af substituerede alpha-amino-indanderivater
AR050709A1 (es) Metodo para preparar irbesartan e intermediarios del mismo
ES2570309T3 (es) Método para la producción de óxido de rosas cis
Pan et al. Organocatalytic asymmetric biomimetic transamination of α-keto acetals to chiral α-amino acetals
EA200900008A1 (ru) Новые хиральные промежуточные продукты, способ их получения и их применение в производстве толтеродина, фезотеродина или их активных метаболитов
EA200500204A1 (ru) Новый способ синтеза (7-метокси-1-нафтил)ацетонитрила и его применение при синтезе агомелатина
EA200500237A1 (ru) Новый способ синтеза соединений 1,3-дигидро-2h-3-бензазепин-2-она и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
UY32500A (es) Nuevo procedimiento de síntesis de la ivabradina y de sus sales de adición a un ácido farmacéuticamente aceptable
PE20131097A1 (es) Nuevo procedimiento de sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
ES2529433T3 (es) Aditivos de continuidad y su utilización en procesos de polimerización
BR0208628A (pt) Processo para produzir compostos de truncamida a